BAM Wealth Management LLC Acquires Shares of 1,858 Thermo Fisher Scientific Inc. $TMO

BAM Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,858 shares of the medical research company’s stock, valued at approximately $901,000.

A number of other large investors have also recently bought and sold shares of TMO. Trek Financial LLC increased its stake in Thermo Fisher Scientific by 40.8% in the third quarter. Trek Financial LLC now owns 3,091 shares of the medical research company’s stock valued at $1,499,000 after purchasing an additional 896 shares during the period. Modera Wealth Management LLC increased its position in Thermo Fisher Scientific by 16.8% in the 3rd quarter. Modera Wealth Management LLC now owns 5,052 shares of the medical research company’s stock valued at $2,450,000 after acquiring an additional 725 shares during the period. PFG Investments LLC raised its stake in Thermo Fisher Scientific by 8.1% during the 3rd quarter. PFG Investments LLC now owns 2,192 shares of the medical research company’s stock valued at $1,063,000 after acquiring an additional 164 shares during the last quarter. GHP Investment Advisors Inc. lifted its position in Thermo Fisher Scientific by 1.3% during the 3rd quarter. GHP Investment Advisors Inc. now owns 5,654 shares of the medical research company’s stock worth $2,742,000 after acquiring an additional 72 shares during the period. Finally, Inlet Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $204,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.2%

Shares of Thermo Fisher Scientific stock opened at $625.42 on Friday. The company has a 50-day moving average of $590.88 and a two-hundred day moving average of $530.87. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a market cap of $234.98 billion, a PE ratio of 36.13, a price-to-earnings-growth ratio of 4.21 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.28 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Morgan Stanley increased their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Citigroup upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their target price for the stock from $580.00 to $660.00 in a research note on Thursday, December 11th. Stifel Nicolaus boosted their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Insiders Place Their Bets

In related news, COO Michel Lagarde sold 22,046 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This represents a 20.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. The trade was a 32.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 131,767 shares of company stock worth $76,467,793. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.